Private equity (PE) investors have long poured money into the healthcare industry, commonly investing in physician practices and hospitals. But in the past couple of years, a new sector is gaining momentum among investors: pharma services.
The sector comprises companies that provide any services to the biopharmaceutical industry, from preclinical development and clinical trials to manufacturing, distribution, and commercialization, according to Rebecca Springer, lead healthcare analyst at global market data company PitchBook, which released a report in June outlining PE interest in pharma services.
“Although PE investment in pharma services reaches back to the 1990s, the past decade has seen industry trends converge to make the space increasingly attractive, and over the past two years, pharma services has become the hottest area of PE healthcare investing,” the report stated.
Keep reading here.—MA
|